NCT07146503View on ClinicalTrials.gov

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2030

Conditions
Depression and Quality of LifeTreatment Resistant Depression (TRD)AnhedoniaApathyAnxietyCognitionTemperamentPsychiatric Comorbidities
Interventions
DRUG

Esketamine (Intranasal Spray)

Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling

Trial Locations (4)

16132

RECRUITING

Ospedale Policlinico San Martino, Genova

16158

RECRUITING

Csm Dds 8, Genova

20157

RECRUITING

ASST Fatebenefratelli Sacco, Milan

66100

RECRUITING

Università di Chieti, Chieti

All Listed Sponsors
lead

Riccardo Guglielmo

OTHER